Norsk Hydro's innovation subsidiary Pronova has had its Omacor drug approved for treatment of post-infarct patients. It will soon be launched on several European markets, after approval in the UK, Germany, France, Austria and Greece. Omacor was developed in Hydro's research centre in Porsgrunn, in Norway, and is claimed to be the first ever therapeutic drug developed in the country. It will be made in Hydro's facility in Sandefjord. The active ingredients are EPA/DHA ethyl esters. Pronova Biocare has signed an agreement with France's Pierre Fabre for the sale and marketing of the drug in France.